Financial Performance - The company recorded revenue of approximately HKD 346.9 million for the six months ended September 30, 2024, a decrease from HKD 357.8 million in the same period of 2023, representing a decline of about 3.3%[3] - The net profit after tax for the reporting period was approximately HKD 17.1 million, a significant recovery from a loss of HKD 8.7 million in the same period of the previous year[5] - Basic earnings per share (EPS) for the period was approximately HKD 2.83, compared to a loss per share of HKD 1.05 in the prior year[5] - The total comprehensive income for the period was HKD 16.0 million, a recovery from a comprehensive loss of HKD 9.6 million in the same period last year[7] - The total profit before tax was HKD 19,302,000, compared to a loss of HKD 8,182,000 in the same period of 2023[30][36] Revenue Breakdown - The revenue from the apparel business was HKD 244,981,000, down 10.9% from HKD 274,964,000 year-on-year[27] - The healthcare products business generated revenue of HKD 73,408,000, an increase of 12.5% from HKD 65,060,000 in the previous year[27] - The IRO and CRO services reported revenue of HKD 28,489,000, up 60.5% from HKD 17,805,000 in the same period last year[27] - The revenue from major customer A in the apparel business was HKD 148,419,000, down from HKD 154,349,000 in the previous year[41] - The apparel segment's revenue decreased by approximately HKD 30 million or 10.9%, from HKD 275 million to HKD 245 million, primarily due to reduced orders from major clients in the US and Japan[81] Cost and Expenses - Research and development expenses totaled HKD 7.4 million, while selling and distribution expenses were HKD 20.2 million, indicating a focus on maintaining operational efficiency[5] - Administrative expenses decreased from approximately HKD 32.1 million to HKD 27.6 million, a reduction of about 14.0% due to lower employee costs and legal fees[98] - The total employee cost for the six months ended September 30, 2024, was approximately HKD 26.5 million, compared to HKD 27.6 million for the same period in 2023[117] Assets and Liabilities - The company reported total assets of HKD 253.8 million as of September 30, 2024, an increase from HKD 211.9 million as of March 31, 2024[10] - Current liabilities increased to HKD 179.2 million from HKD 205.0 million, indicating a reduction in short-term financial obligations[10] - The net current assets improved significantly to HKD 74.7 million, compared to HKD 6.9 million in the previous period, showcasing better liquidity[10] - The total assets as of September 30, 2024, amounted to HKD 474,950,000, an increase from HKD 429,885,000 as of March 31, 2024[37] - The total liabilities as of September 30, 2024, were HKD 298,752,000, compared to HKD 291,703,000 as of March 31, 2024[37] Dividends and Share Capital - The company did not recommend the payment of an interim dividend for the reporting period, reflecting a conservative approach to cash management[3] - The company did not declare any interim dividends for the current period[51][52] - As of September 30, 2024, the company's issued share capital is HKD 5.2 million, divided into 522,177,419 shares with a par value of HKD 0.01 each[108] Strategic Initiatives - The company is exploring new production sources and product development to maintain profitability in the apparel business[70] - The company is pursuing innovative research in regenerative medicine and potential treatments for obesity and diabetes[67] - The company is focusing on understanding customer preferences and identifying emerging trends to design products that drive sustainable long-term growth[118] - The company is exploring new sales structures and business models to maximize profits in response to increasing demand for healthcare products in China[120] Governance and Compliance - The company has adopted corporate governance practices and has complied with all relevant codes during the reporting period, except for a deviation regarding the roles of the chairman and CEO[121] - The audit committee consists of three members, including independent non-executive directors, and has reviewed the unaudited interim results for the reporting period[128]
EPS创健科技(03860) - 2025 - 中期业绩